Fluad Adjuvant Could Come Under Fire At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.